Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: the MYRROR study

Ikuno Y. et al, Ophthalmology, 2015. 122(6):1220-7.

Design

International sham-controlled, double-masked, randomized, Phase 3 study

122 patients

Active CNV from high myopia

BCVA 35 to 73 ETDRS letters



Randomized 3:1

n=91 → **Aflibercept (2mg)**



n=31 → **Sham**



Baseline

Sham injections to week 20

Week 24

+PRN

For activity at monthly visits to week 44

Aflibercept 2mg

+PRN Aflibercept 2mg

For activity at monthly visits to week 44

Week 48



Outcome measures:

Mean change in BCVA at week 24 & 48

Mean change in CRT at week 24 & 48

Safety at week 48

Results

Aflibercept



4.2

Mean number of Aflibercept injections

Sham



3.0



Mean change in BCVA

+12.1 letters	**24 weeks** P < 0.0001	**-2.0 letters**
+13.5 letters	**48 weeks** P < 0.0001	**+3.9 letters**

Aflibercept



Sham



Mean change in CRT

↓80.7µm	**24 weeks**	**↓13.9µm**

Difference (95% C.I.): -94.3 to -41.1µm

↓86.2µm	**48 weeks**	**↓74.0µm**

Difference (95% C.I.): -37.2 to 14.8µm

7.7%	**Serious adverse events**	**3.2%**
71.4%	**Adverse events**	**64.5%**

Conclusions

Intravitreal aflibercept is effective in the treatment of myopic choroidal neovascularization